Literature DB >> 22008817

Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice.

Daisuke Ishibashi1, Hitoki Yamanaka, Tsuyoshi Mori, Naohiro Yamaguchi, Yoshitaka Yamaguchi, Noriyuki Nishida, Suehiro Sakaguchi.   

Abstract

Prions, the causative agents of prion diseases, are immunologically tolerated because their major component, prion protein (PrP), is a host-encoded molecule. Therefore, no effective prion vaccines have been developed. We previously showed that heterologous bovine and sheep PrP immunizations of mice overcame tolerance by an antigenic mimicry mechanism to efficiently induce anti-PrP auto-antibodies (Abs), significantly prolonging incubation times in mice subsequently infected with the mouse-adapted Fukuoka-1 prion. These results prompted us to investigate if non-mammal derived molecules able to antigenically mimic anti-prion epitopes, could act as prion vaccines. We show here that immunization of mice with recombinant succinylarginine dihydrolase, a bacterial enzyme with a peptide sequence similar to an anti-prion epitope, induced anti-PrP auto-Abs with anti-prion activity and significantly retarded survival times of the mice subsequently infected with Fukuoka-1 prions. These results might open a way for development of a new type of antigenic mimicry-based prion vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008817     DOI: 10.1016/j.vaccine.2011.10.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

2.  Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.

Authors:  Daisuke Ishibashi; Takeshi Ishikawa; Satoshi Mizuta; Hiroya Tange; Takehiro Nakagaki; Tsuyoshi Hamada; Noriyuki Nishida
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 3.  The immunobiology of prion diseases.

Authors:  Adriano Aguzzi; Mario Nuvolone; Caihong Zhu
Journal:  Nat Rev Immunol       Date:  2013-11-05       Impact factor: 53.106

4.  Ubiquitin-specific protease 14 modulates degradation of cellular prion protein.

Authors:  Takujiro Homma; Daisuke Ishibashi; Takehiro Nakagaki; Takayuki Fuse; Tsuyoshi Mori; Katsuya Satoh; Ryuichiro Atarashi; Noriyuki Nishida
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

5.  Type I interferon protects neurons from prions in in vivo models.

Authors:  Daisuke Ishibashi; Takujiro Homma; Takehiro Nakagaki; Takayuki Fuse; Kazunori Sano; Katsuya Satoh; Tsuyoshi Mori; Ryuichiro Atarashi; Noriyuki Nishida
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

6.  Strain-Dependent Effect of Macroautophagy on Abnormally Folded Prion Protein Degradation in Infected Neuronal Cells.

Authors:  Daisuke Ishibashi; Takujiro Homma; Takehiro Nakagaki; Takayuki Fuse; Kazunori Sano; Hanae Takatsuki; Ryuichiro Atarashi; Noriyuki Nishida
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

7.  Structure-Based Drug Discovery for Prion Disease Using a Novel Binding Simulation.

Authors:  Daisuke Ishibashi; Takehiro Nakagaki; Takeshi Ishikawa; Ryuichiro Atarashi; Ken Watanabe; Felipe A Cruz; Tsuyoshi Hamada; Noriyuki Nishida
Journal:  EBioMedicine       Date:  2016-06-08       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.